Antibody Drug Conjugates (ADC) Market To Hit USD 29.10 Billion By 2032, Driven By Rising Cancer Cases
Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...
Global Peptide-Drug Conjugate Market to Show Enormous Growth at a CAGR of ~29% by 2032 | DelveInsight
DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...
Pacylex Pharmaceuticals Presents Progress on NMT Inhibitors for Cancer at February Industry Conferences
Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...
Akari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on ...
Tubulis doses first subject in Phase I/IIa solid tumour therapy trial
Tubulis has dosed the first subject in the multicentre Phase I/IIa 5-STAR 1-01 trial to clinically evaluate its second drug ...
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
AFP10d
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...
Business Wire14d
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody linked to a novel camptothecin derivative (a topoisomerase 1 inhibitor) as its payload. The compound was designed with a novel ADC ...